Open AccessS214: PHASE 1/2 STUDY OF ANBAL‐CEL, NOVEL ANTI‐CD19 CAR‐T THERAPY WITH DUAL SILENCING OF PD‐1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA
Author(s) -
Kim W. S.,
Kim S. J.,
Yoon S. E.,
Kim J. R.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843748.64635.ac
Subject(s) - fludarabine , medicine , refractory (planetary science) , tigit , cyclophosphamide , cd19 , gastroenterology , lymphoma , immunology , t cell , pharmacology , immune system , chemotherapy , biology , astrobiology